rogletimide rogletimide rogletimide, also known as pyridoglutethimide, is a medication which was never marketed. it is related in chemical structure to the sedative/hypnotic drug glutethimide, but instead has pharmacological activity as a selective aromatase inhibitor similar to the related drug aminoglutethimide and has no significant sedative-hypnotic effect. this makes it potentially useful in the treatment of breast cancer, and with fewer side effects than aminoglutethimide, but its lower potency caused it to be unsuccessful in clinical trials. pharmacodynamics of aromatase inhibitors generationmedicationdosage % inhibitionaclassbic50c firsttestolactone250 mg 4x/day p.o. ?type i ? 100 mg 3x/week i.m. ? rogletimide200 mg 2x/day p.o.400 mg 2x/day p.o.800 mg 2x/day p.o.50.6%63.5%73.8%type ii ? aminoglutethimide250 mg mg 4x/day p.o.90.6%type ii4,500 nm secondformestane125 mg 1x/day p.o.125 mg 2x/day p.o.250 mg 1x/day p.o.72.3%70.0%57.3%type i30 nm 250 mg 1x/2 weeks i.m.500 mg 1x/2 weeks i.m.500 mg 1x/1 week i.m.84.8%91.9%92.5% fadrozole1 mg 1x/day p.o.2 mg 2x/day p.o.82.4%92.6%type ii ? thirdexemestane25 mg 1x/day p.o.97.9%type i15 nm anastrozole1 mg 1x/day p.o.10 mg 1x/day p.o.96.7–97.3%98.1%type ii10 nm letrozole0.5 mg 1x/day p.o.2.5 mg 1x/day p.o.98.4%98.9%–>99.1%type ii2.5 nm footnotes: a = in postmenopausal women. b = type i: steroidal, irreversible (substrate-binding site). type ii: nonsteroidal, reversible (binding to and interference with the cytochrome p450 heme moiety). c = in breast cancer homogenates. sources: see template. rogletimideclinical dataother namesroglethimide; pyridoglutethimideroutes ofadministrationby mouthdrug classaromatase inhibitoridentifiers iupac name 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione cas number92788-10-8pubchem cid56487chemspider50963unii14p4qr28qfchemical and physical dataformulac12h14n2o2molar mass218.256 g·mol−13d model (jsmol)interactive image smiles o=c1nc(=o)ccc1(c2ccncc2)cc synthesis synthesis: patent: base catalyzed alkylation of ethyl 4-pyridylacetate (1) with iodoethane gives ethyl 2-(4-pyridyl)butyrate (2). base catalyzed conjugate addition of the carbanion to acrylamide (3) gives (4). the last step is an intramolecular cyclization to rogletimide (5).